Sexual Health Impact of Using Pre-exposure HIV Prophylaxis (SatisPreP)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Brioude, France
- CH Brioude
-
Clermont-Ferrand, France
- CHU clermont-ferrand
-
Clermont-Ferrand, France
- CEGIDD Clermont Ferrand
-
Le Puy-en-Velay, France
- CH Le Puy en Velay
-
Montluçon, France
- Ch Montlucon
-
Moulins, France
- Ch Moulins
-
Vichy, France
- CH VICHY
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patient, male having sex with men, not infected with HIV, and using HIV prophylaxis by pre-exposure treatment (PrEP) for at least 1 year, received in consultation for renewal of this prescription.
- Able to give his non-opposition to participate in the research.
- Affiliation to a social security scheme.
Exclusion Criteria:
- Patient under curatorship/guardianship or safeguard of justice
- Refusal to participate
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sexual health satisfaction
Time Frame: 1 day during the scheduled consultation
|
To study the sexual health satisfaction of men who have sex with men (MSM), since the use of HIV prophylaxis by pre-exposure treatment (PrEP), compared to the time before PrEP.
|
1 day during the scheduled consultation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sentimental satisfaction
Time Frame: 1 day during the scheduled consultation
|
To study the sentimental satisfaction since the use of HIV prophylaxis by treatment before exposure (PrEP), compared to the time before PrEP.
|
1 day during the scheduled consultation
|
|
Risky behaviours
Time Frame: 1 day during the scheduled consultation
|
To study risky behaviours without, then on PrEP since the use of HIV prophylaxis by treatment before exposure (PrEP), compared to the time before PrEP.
|
1 day during the scheduled consultation
|
|
Specific care
Time Frame: 1 day during the scheduled consultation
|
Describe the use of specific care during PrEP.
|
1 day during the scheduled consultation
|
|
Predictors of satisfaction
Time Frame: 1 day during the scheduled consultation
|
Define possible predictors of satisfaction with PrEP.
|
1 day during the scheduled consultation
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- RNI 2021 JACOMET
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.